Past Events

May 11, 2022 10:00 AM EDT
May 10, 2022 12:40 PM PDT
Feb 16, 2022 8:00 AM EST
Nov 10, 2021 8:00 AM EST
Nov 8, 2021 10:30 AM EST

Galecto will host a key opinion leader event to discuss the current treatment landscape for NSCLC, as well as the potential for GB1211, Galecto’s galectin-3 inhibitor that is expected to enter a phase 2 trial in 1H 2022.

Jun 9, 2021

Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter.

Mar 30, 2021